Drugs in the Pipeline
The submission was based on data from the double-blind, placebo-controlled VOYAGE trial.
This article is part of MPR’s coverage of the American Academy of Ophthalmology 2019 Meeting, taking place in San Francisco, CA. Our staff will report on medical research related to eye disorders, conducted by experts in the field. Check back regularly for more news from AAO 2019. SAN FRANCISCO – For patients with progressive Acanthamoeba…
The FDA has approved Zeposia® (ozanimod) for moderately to severely active ulcerative colitis in adults.
In their presentation, Ahmad R. Sedaghat, MD, PhD and Stacey T. Gray, MD, FACS discuss both patient and physician perspectives for successful control of CRS.